MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.150
+0.190
+4.80%
After Hours: 4.180 +0.03 +0.72% 17:45 09/24 EDT
OPEN
3.920
PREV CLOSE
3.960
HIGH
4.240
LOW
3.900
VOLUME
602.21K
TURNOVER
--
52 WEEK HIGH
5.70
52 WEEK LOW
1.820
MARKET CAP
245.99M
P/E (TTM)
-8.2983
1D
5D
1M
3M
1Y
5Y
BRIEF-Galectin Therapeutics Inc Says Co And Richard E. Uihlein Entered Into A Loan Agreement In Aggregate Of $20.0 Mln
reuters.com · 4d ago
BRIEF-Galectin Therapeutics Announces $20 Million Convertible Debt Financing From Its Chairman, Richard E. Uihlein
reuters.com · 4d ago
Galectin Secures $20 Million Debt Financing from Chairman Richard Uihlein
MT Newswires · 4d ago
Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company’s management will present at the H.C. Wainwright 23rd Annual Globa...
GlobeNewswire · 09/09 13:00
BRIEF-Galectin Therapeutics Reports Quarterly Loss Per Share Of $0.15
reuters.com · 08/16 13:14
Galectin Therapeutics Q2 EPS $(0.15) Down From $(0.11) YoY
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share. This is a 36.36 percent decrease over losses of $(0.11) per share from the same period last year.
Benzinga · 08/16 13:06
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.
Benzinga · 08/03 08:45
VXRT, SAVA And GALT among pre-market gainers
Ever-Glory (NASDAQ:EVK) +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Mode...
Seekingalpha · 08/02 12:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GALT. Analyze the recent business situations of Galectin Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GALT stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 9.13M
% Owned: 15.40%
Shares Outstanding: 59.28M
TypeInstitutionsShares
Increased
13
311.63K
New
21
1.40M
Decreased
20
3.24M
Sold Out
20
491.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Richard Uihlein
President/Chief Executive Officer/Director
Joel Lewis
Chief Financial Officer
Jack Callicutt
Executive Vice President
Eliezer Zomer
Vice President
J. Rex Horton
Other
Pol Boudes
Director
Harold Shlevin
Independent Director
Gilbert Amelio
Independent Director
James Czirr
Independent Director
Kary Eldred
Independent Director
Kevin Freeman
Independent Director
Gilbert Omenn
Independent Director
Marc Rubin
Independent Director
Elissa Schwartz
Independent Director
Richard Zordani
No Data
About GALT
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.